NEW YORK, June 20 - Oxford Glycosciences and NeoGenesis have agreed to partner in an effort to identify small molecule drugs for OGS' protein targets, the companies said Wednesday. 

OGS, of Oxford, UK, will provide an undisclosed number of protein targets to NeoGenesis, and pay NeoGenesis research fees, milestone payments, and royalties for lead compounds that the company identifies. OGS will commercialize any lead compounds, and is also making an undisclosed equity investment in NeoGenesis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.